Dongsheng Tu

Dongsheng Tu

Queens University

H-index: 82

Asia-Bangladesh

About Dongsheng Tu

Dongsheng Tu, With an exceptional h-index of 82 and a recent h-index of 45 (since 2020), a distinguished researcher at Queens University, specializes in the field of biostatistics, clinical trials.

His recent articles reflect a diverse array of research interests and contributions to the field:

Consistent covariances estimation for stratum imbalances under minimization method for covariate‐adaptive randomization

The association of healthcare contact days with physical function and survival in CCTG/AGITG CO. 17

A threshold mixed-effects Tobit model for treatment-sensitive subgroup identification based on longitudinal measures with floor and ceiling effects and a continuous covariate

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO. 17 and CO. 20 Randomized Clinical Trials

738 Surgical approach, preoperative LEEP/cone biopsy and patterns of recurrence and death in low-risk cervical cancer–analysis of the international CCTG CX. 5/SHAPE phase III trial

Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer

Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Dongsheng Tu Information

University

Position

Professor of Biostatistics Canada

Citations(all)

49406

Citations(since 2020)

10832

Cited By

42640

hIndex(all)

82

hIndex(since 2020)

45

i10Index(all)

226

i10Index(since 2020)

147

Email

University Profile Page

Google Scholar

Dongsheng Tu Skills & Research Interests

biostatistics

clinical trials

Top articles of Dongsheng Tu

Consistent covariances estimation for stratum imbalances under minimization method for covariate‐adaptive randomization

Scandinavian Journal of Statistics

2024

Yanglei Song
Yanglei Song

H-Index: 6

Dongsheng Tu
Dongsheng Tu

H-Index: 48

The association of healthcare contact days with physical function and survival in CCTG/AGITG CO. 17

JNCI: Journal of the National Cancer Institute

2024/4/24

A threshold mixed-effects Tobit model for treatment-sensitive subgroup identification based on longitudinal measures with floor and ceiling effects and a continuous covariate

Journal of Statistical Computation and Simulation

2024/4/23

Yingwei Peng
Yingwei Peng

H-Index: 26

Dongsheng Tu
Dongsheng Tu

H-Index: 48

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO. 17 and CO. 20 Randomized Clinical Trials

Clinical Cancer Research

2024/1/30

738 Surgical approach, preoperative LEEP/cone biopsy and patterns of recurrence and death in low-risk cervical cancer–analysis of the international CCTG CX. 5/SHAPE phase III trial

2024/3/1

Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer

New England Journal of Medicine

2024/2/29

Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction

Statistics in Biopharmaceutical Research

2024/1/4

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

The Lancet

2021/8/28

Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients with Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial

JAMA Network Open

2023/12/1

A phase II study of durvalumab re-treatment+/-prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND. 238A).

2023/6/1

Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer

Clinical Colorectal Cancer

2023/12/1

Geoffrey Liu
Geoffrey Liu

H-Index: 4

Dongsheng Tu
Dongsheng Tu

H-Index: 48

A generalized single‐index linear threshold model for identifying treatment‐sensitive subsets based on multiple covariates and longitudinal measurements

Canadian Journal of Statistics

2023/12

Yingwei Peng
Yingwei Peng

H-Index: 26

Dongsheng Tu
Dongsheng Tu

H-Index: 48

A composite semiparametric homogeneity test for the distributions of multigroup interval-bounded longitudinal data

Journal of Biopharmaceutical Statistics

2023/11/13

Hao Ding
Hao Ding

H-Index: 7

Dongsheng Tu
Dongsheng Tu

H-Index: 48

Brief report: canadian cancer trials group IND. 227: A phase 2 randomized study of pembrolizumab in patients with advanced Malignant pleural mesothelioma (NCT02784171)

Journal of Thoracic Oncology

2023/6/1

A threshold longitudinal Tobit quantile regression model for identification of treatment‐sensitive subgroups based on interval‐bounded longitudinal measurements and a …

Statistics in Medicine

2023/11/10

Tao Li
Tao Li

H-Index: 10

Dongsheng Tu
Dongsheng Tu

H-Index: 48

Evaluating the time toxicity of cancer treatment in the CCTG CO. 17 trial

JCO Oncology Practice

2023/6

# 142 An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in …

2023/9/1

Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer

Cancer Medicine

2023/8

Hans J Vogel
Hans J Vogel

H-Index: 45

Dongsheng Tu
Dongsheng Tu

H-Index: 48

Abstract P3-07-18: CCTG IND. 239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)

Cancer Research

2023/3/1

See List of Professors in Dongsheng Tu University(Queens University)

Co-Authors

academic-engine